EUVIMEDEUVIMED entdecken
Crossref

Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss

The Medical Letter on Drugs and Therapeutics · 25.05.2026 · 68 (1755) · 81-83

DOI: 10.58347/tml.2026.1755a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 25.05.2026. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved orforglipron (Foundayo – Lilly), an oral small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbidity. Orforglipron is the second oral GLP-1 receptor agonist to be approved in the US for this indication; an oral formulation of the peptide semaglutide (Wegovy) was approved in 2025.

Schlagwörter

Stichwörter der Autor:innen

FoundayoWegovyadverse effectsdosagedrug interactionsefficacylactationorforglipronpregnancysafetysemaglutideweight loss

Zitieren

APA

(2026). Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss. The Medical Letter on Drugs and Therapeutics, 68(1755), 81-83. https://doi.org/10.58347/tml.2026.1755a

Vancouver

Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss. The Medical Letter on Drugs and Therapeutics. 2026;68(1755):81-83. doi:10.58347/tml.2026.1755a

BibTeX
@article{euvimed2026,
  title = {Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1755},
  pages = {81--83},
  doi = {10.58347/tml.2026.1755a}
}
Kostenlos starten →